Non motor subtypes and Parkinson's disease

https://doi.org/10.1016/j.parkreldis.2015.09.027Get rights and content

Highlights

  • Clinical and neurobiological research suggests existence of discrete NM subtypes, particularly in untreated/early PD patients.

  • Description of six NMS dominant phenotypes of PD combining clinical, biomarker and pathophysiological concepts.

  • NMS subtyping would enrich the design of clinical trials and recruitment of patients.

  • NNMS subtyping would improve the knowledge about the natural history of PD so far only addressed for motor symptoms.

Abstract

Non motor symptoms (NMS) represent a significant burden in Parkinson's disease (PD) with numerous studies highlighting the importance of NMS both in “pre-motor” phase of PD as well as throughout the course of disease. In part this has led the international Parkinson and Movement Disorder Society (IPMDS) task force to attempt a re-definition of PD incorporating NMS and not base the diagnosis solely on motor symptoms. While motor subtypes within PD have been recognized and researched, recent clinical and neurobiological research suggests the existence of discrete non motor subtypes in PD, particularly in untreated (drug naïve) and early PD patients. Several independent observers have reported specific “clusters of NMS dominant PD” using a data driven approach in early and untreated PD patients while others have reported on the burden of NMS in untreated PD and specific NMS dominant phenotypes in untreated or treated PD using observational case series based data. In this review we report on specific NMS dominant phenotypes of PD as described in the literature using clinical observational studies and address pathophysiological concepts. A proposal for several NMS subtypes are reported combining clinical reports with, where possible, evidence base supporting probable biomarkers.

Introduction

Motor symptoms of Parkinson's disease (PD) such as tremor, bradykinesia and rigidity are the hallmark based on which diagnosis and treatment are started and are now known to be preceded by the “pre-motor” phase of PD largely dominated by a range of different non motor symptoms (NMS) [1], [2], [3].

Virtually every PD patient has NMS, which are now widely recognized as an important unmet need in PD [3] and a major determinant of health related quality of life (HrQoL) of patients with PD and their carers [4]. In a survey by Parkinson's UK, patients listed NMS such as pain, sleep disorders and anxiety ahead of motor problems in clinical importance, and two further studies have outlined the key impact of NMS as declared by patients themselves [3], [32].

Despite this importance, little has been done to establish NMS clinical phenotypes in the context of the multi-morbid PD patient even though several workers have reported clinical phenotypes driven by specific NMS such as pain, cognitive problems, apathy and sleep dysfunction. Additionally, cluster analysis from several large early and untreated PD cohorts have all suggested specific NMS dominant or only NMS driven clustering [12], [13], [14]. This review aims to highlight these phenotypic variants that have been described within the rubric of Parkinson's disease.

NMS based subtyping of PD is plausible from a clinical point of view that in some PD patients, but not all, specific NMS are predominantly expressed, while in others NMS may not be evident or are less relevant. The clinical expression of a range of NMS highlights the fact that the phenotype of PD results from varying rates of Lewy body deposition and neurodegeneration in PD and represents the effects of widespread brain and peripheral Lewy body pathology instead of a single neural structure affected or the loss of the monoamine neurotransmitter such as dopamine [3], [5]. This convergence of deficits in multiple transmitter systems and pathways, including the cholinergic, noradrenergic, and serotonergic systems, may all be associated with clinical expression of NMS. In addition, glial pathology, neuroimmune responses, and proinflammatory cytokines may also play a key pathogenic role adding to the heterogeneity of PD [5], [6]. Furthermore, non-dopaminergic areas in the brainstem may be affected and involved ahead of dopaminergic involvement as recently reviewed by Todorova et al. [3], [5], [6], [7]. Jellinger has suggested that neuropathological spread of the neurodegenerative process may be initiated via the olfactory bulb and thereafter through the limbic or brainstem areas while spread via the enteric nervous system via the nervus vagus has also been suggested [5], [6], [7], [8]. A limbic, brainstem and cortical dominant pathophysiological process as proposed by Braak et al. [11], Jellinger et al. [5], Beach et al. [9] or Halliday et al. [7] is the basis of our proposal as shown in Fig. 1. All of these processes would lead to dominant expression of NMS over motor symptoms as also underpinned by the Braak hypothesis of α-synuclein accumulation starting in the lower brainstem and the olfactory bundle well before there is significant involvement of substantia nigra [11].

NMS subtyping is thus based on the evidence that early and substantial neuronal loss occurs in many non-dopaminergic nuclei in the limbic and brainstem areas, either before or concomitantly with involvement of dopaminergic projections [5], [9], [10]. The dorsal motor nucleus of the vagus (DMV) is a key area for control of autonomic signaling responsible for symptoms such as constipation. Neuronal loss in the DMV could be as profound as that in the substantia nigra (SN), and large (43–57% loss) cholinergic and substance P expressing neurons are preferentially lost while tyrosine hydroxylase neurons may be relatively spared in PD [5], [10].

A further contributor in the pathophysiology of non motor subtypes within PD is the age of onset of PD. Preferential Lewy body deposition in the brainstem in young onset PD versus a cortical dominant pathology in late onset PD has been described, the latter being associated with Alzheimer's disease type pathology [7], [11].

It is likely therefore, in these subjects patterns of NMS, dependent on relevant neuropathological involvement of non-dopaminergic areas, will underpin the clinical expression of specific NMS such as sleep problems, apathy, pain, depression/anxiety, ahead of and dominating the typical motor deficit of PD.

Untreated PD patients represent a suitable model to study the expression of NMS in comparison to motor symptoms. Erro et al. have conducted a cluster analysis coupled with validated cognitive, motor and nonmotor assessments in a untreated PD cohort and found 4 discrete clusters within the cohort termed benign pure motor, benign mixed motor-non-motor, nonmotor dominant and motor dominant [12]. The non motor dominant cluster reported higher urinary dysfuction and a rapid progression rate compared to the benign mixed motor, nonmotor cluster.

In the recently reported ONSET-PD study, the authors highlighted specific non motor clusters of PD ranging from cognitive and mood clusters to sensory, RBD dominant and autonomic dysfunction related cluster further supporting our attempt of NM subtying of PD [13]. Studies have also identified specific clinical phenotypes in untreated PD underpinned by NMS such as sleep dysfunction, cognitive and neurosychiatric disturbances (depression, apathy), fatigue, dysautonomia, pain and olfaction recently reviewed by Zis et al. [14]. These observations fit well with the neuropathological studies, which have suggested a differential rate of neuronal degeneration and Lewy body deposition in the non-dopaminergic brainstem and limbic areas in PD, with consequent expression of a variety of related NMS.

Section snippets

The literature descriptions of specific NMS dominant subtypes of PD

A proposal of at least six different NMS dominant clinical phenotypes within PD mainly in early and untreated phase has been proposed based on clinical observation and in this review we discuss the patterns that have been reported and published so far [15].

The problems of non-motor subtyping

As PD is a heterogeneous disorder there is considerable possibility that these subtypes will overlap and are likely to be present only in a proportion of patients. Comparable with the instability of motor subtypes, non-motor subtypes will change throughout the course of disease and at the end several types will merge and overlap. As such we accept that the classification is a simplification with heterogeneity and overlapping probably existing within these proposed major subtypes.

Selection bias

Conclusion

NMS subtyping in PD is a new concept and as shown in this paper, is clinically relevant and possible. The process emphasizes the value of incorporating NMS as an obligatory clinic assessment which aims to ensure that NMS are not missed in the clinic currently dominated by motor assessment and leads to sub-optimal care. Subtyping of clinically heterogeneous conditions is possible and regarded as routine clinical practice in conditions such as multiple sclerosis, motor neuron disease, and

Conflict of interest statement

The authors do not report any conflicts of interest.

Author declaration

The author declaration will be submitted offline.

References (33)

  • A.E. Kingsbury et al.

    Brain stem pathology in PD disease: an evaluation of the Braak staging model

    Mov. Disord.

    (2010)
  • G. Halliday et al.

    Milestones in Parkinson's disease-clinical and pathological features

    Mov. Disord.

    (2011)
  • K. Del Tredici et al.

    Where does Parkinson disease pathology begin in the brain?

    J. Neuropathol. Exp. Neurol.

    (2002)
  • T.G. Beach et al.

    Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction

    Acta Neuropathol.

    (2009)
  • W.P. Gai et al.

    Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease

    Brain

    (1991)
  • R. Erro et al.

    The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients

    PLoS One

    (2013)
  • Cited by (254)

    • Refining the clinical diagnosis of Parkinson's disease

      2024, Parkinsonism and Related Disorders
    View all citing articles on Scopus
    View full text